BRAF and cancer: Although the panRAF inhibitor TAK-632, and the BRAF inhibitors PLX4720 and dabrafenib inhibit BRAF more potently than CCT3833 in in vitro enzyme assays, CCT3833 is more potent at inhibiting KRAS-mutant cancer cell growth, so we examine downstream signaling.